Genmab Reports on Recruitment in HuMax-CD20 Study

Denmark’s Genmab has recruited 132 patients in a study of HuMax-CD20 for the treatment of refractory chronic lymphocytic leukemia.

The group includes 66 patients who are refractory to fludarabine and alemtuzumab and 66 fludarabine-refractory patients who are considered inappropriate candidates for alemtuzumab due to a bulky tumor in their lymph nodes.

An interim analysis will be conducted when 24-week efficacy data are available. The study will remain open for recruitment to collect additional safety and efficacy data, Genmab said.

HuMax-CD20 (ofatumumab) is a monoclonal antibody being developed under an agreement between Genmab and GlaxoSmithKline.